The firm no longer sees an actionable short with the shares now close to its price tar NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage ...

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the ...

TOURMALINE BIO ($TRML) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.86 per share, beating estimates of -$0.89 by $0 ...

My last article some years back noted that Charlie Lake had a lot of profit potential, and Tourmaline was there first. As the slide above shows, Charlie Lake has one of the best profit potentials ...

Fintel reports that on March 6, 2025, Wedbush initiated coverage of Tourmaline Bio (NasdaqGS:TRML) with a Outperform ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

The market expects Tourmaline Oil Corp. (TRMLF) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known ...

Tourmaline Oil Corp. closed 11.2% below its 52-week high of C$70.83, which the company reached on February 21st.

Wedbush initiated coverage of Tourmaline Bio (TRML) with an Outperform rating and $42 price target Discover the Best Stocks and Maximize Your ...

Last week, you might have seen that Tourmaline Oil Corp. ( TSE:TOU ) released its full-year result to the market.

Shares of Tourmaline Oil Corp. TOU inched 0.05% higher to C$64.85 Tuesday, in what proved to be an otherwise all-around poor trading session for the Canadian market, with the S&P/TSX Composite ...